GO:0061513 glucose 6-phosphate:phosphate antiporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061513 describes a molecular function that exchanges glucose 6-phosphate (G6P) and inorganic phosphate (Pi) across a membrane.
• The SLC37 family members SLC37A1, SLC37A2, SLC37A3, and SLC37A4 (G6PT) are the principal proteins annotated with this activity.
• The reaction is a strict antiport: G6P moves in one direction while Pi moves in the opposite direction, with no net charge imbalance.
• Deficiency of the G6P transporter SLC37A4 causes glycogen storage disease type Ib and Ic, characterized by hypoglycemia and neutropenia.
• Structural and functional studies have revealed a reciprocal antiport mechanism driven by conformational changes in the transporter.
• Research on this activity employs vesicle transport assays, site-directed mutagenesis, and CRISPR-based models to dissect substrate specificity and disease mechanisms.
Description
Glucose 6-phosphate:phosphate antiporter activity (GO:0061513) is a molecular function that enables the coupled exchange of glucose 6-phosphate (G6P) and inorganic phosphate (Pi) across biological membranes. This activity is essential for maintaining metabolic homeostasis, particularly in the liver, kidney, and intestine, where it facilitates the final steps of gluconeogenesis and glycogenolysis. The antiporter ensures that G6P, a key intermediate in carbohydrate metabolism, can be transported into the endoplasmic reticulum (ER) in exchange for Pi, thereby regulating glucose production. The physiological importance of this activity is underscored by its association with glycogen storage disease type Ib (GSD Ib) and type Ic (GSD Ic), which result from mutations in the SLC37A4 gene encoding the G6P transporter (G6PT). These disorders present with severe hypoglycemia, hepatomegaly, and immune dysfunction, highlighting the critical role of G6P:Pi antiport in systemic glucose homeostasis. Beyond disease, this activity is a target for understanding metabolic regulation and for developing therapeutic strategies in metabolic disorders. Researchers study GO:0061513 to elucidate the molecular mechanisms of sugar-phosphate transport, to characterize the SLC37 family, and to model human metabolic diseases in vitro and in vivo. The antiporter's unique exchange mechanism and its involvement in multiple metabolic pathways make it a compelling subject for structural biology, biochemistry, and CRISPR-based functional genomics.
glucose 6-phosphate:phosphate antiporter activity At A Glance
| GO ID | GO:0061513 |
|---|---|
| GO term | glucose 6-phosphate:phosphate antiporter activity |
| Ontology | molecular_function |
| Synonym | glucose 6-phosphate:inorganic phosphate antiporter activity |
| Major function | Catalyzes the antiport of glucose 6-phosphate and inorganic phosphate across membranes |
| Reaction | glucose 6-phosphate(out) + phosphate(in) = glucose 6-phosphate(in) + phosphate(out) |
| Major proteins | SLC37A1, SLC37A2, SLC37A3, SLC37A4 (G6PT) |
| Associated disease | Glycogen storage disease type Ib and Ic |
| Subcellular location | Endoplasmic reticulum membrane, plasma membrane |
What Is GO:0061513?
GO:0061513, glucose 6-phosphate:phosphate antiporter activity, is defined as the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose 6-phosphate(out) + phosphate(in) = glucose 6-phosphate(in) + phosphate(out). In other words, it is a secondary active transport process that couples the inward movement of glucose 6-phosphate with the outward movement of inorganic phosphate, or vice versa, across a lipid bilayer. This activity is typically mediated by integral membrane proteins of the SLC37 family, which function as phosphate-linked antiporters.
Why Is glucose 6-phosphate:phosphate antiporter activity Important in Cell Biology?
GO:0061513 is critical for metabolic homeostasis because it controls the flux of glucose 6-phosphate, a central metabolite at the intersection of glycolysis, gluconeogenesis, and the pentose phosphate pathway. By exchanging G6P for Pi, the antiporter regulates the availability of G6P for hydrolysis by glucose-6-phosphatase in the ER lumen, thereby influencing blood glucose levels. Dysfunction of this activity leads to glycogen storage diseases, and its modulation may have therapeutic implications for diabetes and metabolic syndrome.
• Maintains blood glucose homeostasis by enabling hepatic glucose production.
• Mutations in SLC37A4 cause glycogen storage disease type Ib and Ic.
• Provides a model for studying phosphate-linked antiport mechanisms.
• Influences redox balance via G6P availability for the pentose phosphate pathway.
• Plays a role in immune function, as GSD Ib patients exhibit neutropenia.
• Serves as a target for understanding drug transport and metabolic regulation.
• Enables the study of membrane protein structure-function relationships.
• Contributes to the pathogenesis of metabolic disorders beyond GSD, such as insulin resistance.
Molecular Mechanism of glucose 6-phosphate:phosphate antiporter activity
Substrate Recognition and Binding
In simple terms: The transporter first grabs glucose 6-phosphate and phosphate from opposite sides of the membrane.
The antiporter selectively binds glucose 6-phosphate (G6P) and inorganic phosphate (Pi) at distinct sites within its transmembrane domains. Structural studies of human G6PT (SLC37A4) have revealed that substrate binding induces local conformational changes that prime the protein for exchange. The binding affinity for G6P is influenced by pH and the presence of Pi, ensuring that transport is tightly coupled.
Conformational Cycling and Antiport
In simple terms: The protein changes shape to move the two molecules in opposite directions across the membrane.
Following substrate binding, the antiporter undergoes a series of conformational transitions that alternately expose the substrate-binding sites to the cytoplasmic and luminal sides of the membrane. This reciprocal antiport mechanism ensures that the inward transport of G6P is strictly coupled to the outward transport of Pi, preventing uncoupled fluxes. Mutagenesis studies have identified residues critical for this cycling, and their alteration can abolish transport activity.
Energetics and Driving Force
In simple terms: The exchange is driven by the concentration gradients of the two molecules, not by ATP.
The antiport is a secondary active transport process; it does not directly consume ATP. Instead, the energy stored in the concentration gradient of Pi (or G6P) drives the exchange. Under physiological conditions, the high luminal Pi concentration in the ER favors G6P uptake, which is then hydrolyzed to glucose and Pi by glucose-6-phosphatase. This coupling maintains the gradient and ensures efficient glucose production.
Regulation by pH and Metabolites
In simple terms: The transporter's activity can be tuned by the acidity and the levels of other molecules in the cell.
The activity of G6P:Pi antiport is sensitive to pH, with acidic conditions modulating substrate affinity and transport rates. Additionally, metabolites such as glucose-6-phosphate dehydrogenase (G6PD) can influence the availability of G6P and the redox state, indirectly affecting antiport activity. These regulatory inputs allow the antiporter to adapt to metabolic demands.
Structural Basis of the Antiport Mechanism
In simple terms: The 3D structure of the protein shows how it can swap the two molecules.
Recent cryo-EM structures of human G6PT have provided a detailed view of the antiport cycle, revealing a rocker-switch mechanism where two halves of the protein move relative to each other. This structural information explains how mutations in SLC37A4 lead to disease and offers a template for designing small-molecule modulators.
Key Genes Involved in GO:0061513 glucose 6-phosphate:phosphate antiporter activity
The following genes encode proteins that exhibit glucose 6-phosphate:phosphate antiporter activity or are directly involved in its regulation and function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC37A1 | Phosphate-linked G6P antiporter | Studied for its role in glucose homeostasis and transport assays |
| SLC37A2 | Phosphate-linked G6P antiporter | Expressed in macrophages; linked to immune function |
| SLC37A3 | Putative G6P antiporter | Less characterized; potential role in metabolic tissues |
| SLC37A4 | G6P transporter (G6PT) | Deficient in GSD Ib/Ic; major disease gene |
| G6PC | Glucose-6-phosphatase catalytic subunit | Works with G6PT in the ER to hydrolyze G6P |
| G6PC2 | Islet-specific glucose-6-phosphatase | May interact with G6PT in pancreatic beta cells |
| G6PC3 | Ubiquitous glucose-6-phosphatase | Associated with neutropenia; potential crosstalk |
| G6PD | Glucose-6-phosphate dehydrogenase | Regulates G6P flux and redox balance |
| SLC2A1 | GLUT1 glucose transporter | Indirectly affects G6P levels and antiport demand |
| SLC2A2 | GLUT2 glucose transporter | Liver-specific; influences G6P availability |
| HK1 | Hexokinase 1 | Phosphorylates glucose to G6P, upstream of antiport |
| HK2 | Hexokinase 2 | Upregulated in cancer; increases G6P production |
| GYS1 | Glycogen synthase 1 | Competes with G6P for storage; affects antiport flux |
| PYGL | Glycogen phosphorylase L | Produces G6P from glycogen; feeds antiport |
| PPP1R3A | Protein phosphatase 1 regulatory subunit | Regulates glycogen metabolism and G6P levels |
| FOXO1 | Transcription factor | Regulates gluconeogenic genes including G6PC and SLC37A4 |
| HNF4A | Hepatocyte nuclear factor 4 alpha | Controls expression of SLC37A4 and metabolic genes |
How Is glucose 6-phosphate:phosphate antiporter activity Regulated?
The expression and activity of glucose 6-phosphate:phosphate antiporters are regulated at multiple levels. Transcriptionally, SLC37A4 is controlled by hepatic nuclear factors such as HNF4A and FOXO1, which respond to hormonal signals like insulin and glucagon. Post-translationally, the transporter's activity can be modulated by phosphorylation and redox modifications, although specific sites remain under investigation. Metabolically, the availability of substrates (G6P and Pi) and the pH of the ER lumen influence transport rates. Additionally, G6PD-mediated redox signaling can indirectly affect antiport activity by altering G6P flux.
glucose 6-phosphate:phosphate antiporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC37A4 | Glycogen storage disease type Ib/Ic | Knockout mouse, patient-derived iPSCs, point-mutation knock-in |
| G6PC | Glycogen storage disease type Ia | Liver-specific knockout, overexpression |
| G6PD | Hemolytic anemia, cancer metabolism | Knockdown, CRISPR knockout |
| SLC2A2 | Fanconi-Bickel syndrome | Knockout zebrafish, knock-in mutations |
| FOXO1 | Insulin resistance, diabetes | Overexpression, conditional knockout |
Glycogen Storage Disease Type Ib and Ic
Mutations in SLC37A4, which encodes the G6P transporter, cause glycogen storage disease type Ib (GSD Ib) and type Ic (GSD Ic). These autosomal recessive disorders are characterized by fasting hypoglycemia, hepatomegaly, nephromegaly, and failure to thrive. GSD Ib uniquely features neutropenia and neutrophil dysfunction, leading to recurrent infections and inflammatory bowel disease. The antiport defect impairs the final step of glucose-6-phosphatase-mediated glucose production, causing G6P accumulation and glycogen overload.
Metabolic Syndrome and Type 2 Diabetes
Altered G6P:Pi antiport activity may contribute to insulin resistance and hyperglycemia in type 2 diabetes. Increased G6P levels in skeletal muscle can inhibit hexokinase and reduce glucose uptake, a hallmark of insulin resistance. While direct mutations in SLC37A4 are not common in type 2 diabetes, dysregulation of the antiporter's expression or activity could exacerbate metabolic dysfunction.
Cancer Metabolism
Cancer cells often exhibit increased glucose uptake and G6P production to support anabolic growth. The G6P:Pi antiporter may play a role in maintaining G6P homeostasis in cancer cells, and its inhibition could selectively starve tumors of glucose-derived intermediates. However, direct evidence linking GO:0061513 to cancer remains limited and requires further investigation.
From glucose 6-phosphate:phosphate antiporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC37A4 loss impair glucose production? | SLC37A4 knockout hepatocytes or mouse models |
| How do disease mutations affect antiport activity? | Point-mutation knock-in of SLC37A4 variants |
| Can wild-type SLC37A4 rescue GSD Ib phenotypes? | Knock-in of tagged SLC37A4 for rescue studies |
| What is the subcellular localization of G6PT? | Tagged knock-in with fluorescent protein |
| Does overexpression of SLC37A1 alter G6P flux? | Overexpression cell lines |
| Which genes interact with SLC37A4 in metabolic networks? | CRISPR library screening and bioinformatics |
How to Study the glucose 6-phosphate:phosphate antiporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled vesicle transport | Antiport activity and kinetics | Characterizing SLC37A4 mutants |
| Cryo-EM | 3D structure of transporter | Mechanistic studies of G6PT |
| CRISPR knockout | Loss-of-function phenotypes | Validating SLC37A4 in glucose production |
| Site-directed mutagenesis | Residue-specific function | Identifying critical amino acids for antiport |
| 13C metabolic flux analysis | Flux through G6P pathways | Quantifying antiport contribution to metabolism |
| RNA-seq | Transcriptional changes | Assessing SLC37A4 expression in disease models |
| Proteomics | Protein interactions and modifications | Identifying G6PT binding partners |
| Live-cell imaging | Subcellular localization | Tracking tagged G6PT in real time |
Transport Assays in Vesicles
Radiolabeled G6P or Pi uptake assays using membrane vesicles from cells expressing SLC37A4 or other SLC37 members are the gold standard for measuring antiport activity. These assays can determine kinetic parameters, substrate specificity, and the effects of mutations.
Structural Biology (Cryo-EM and Crystallography)
High-resolution structures of G6PT have been solved using cryo-electron microscopy, revealing the antiport mechanism and substrate-binding sites. These methods are essential for understanding how disease mutations disrupt function and for structure-based drug design.
CRISPR-Cas9 Genome Editing
CRISPR knockout, knock-in, and point-mutation models allow researchers to study the consequences of SLC37A4 loss or specific mutations in isogenic cell lines. These models are invaluable for dissecting disease mechanisms and testing therapeutic interventions.
Metabolic Flux Analysis
Stable isotope tracing with 13C-labeled glucose can quantify G6P flux through the antiporter and downstream pathways. This approach links antiport activity to broader metabolic networks and can be combined with CRISPR screens.
How CRISPR Can Be Used to Study GO:0061513 glucose 6-phosphate:phosphate antiporter activity
Knockout
CRISPR-Cas9 knockout of SLC37A4 in hepatocyte cell lines or primary cells abolishes G6P:Pi antiport activity, leading to G6P accumulation and impaired glucose production. These models mimic GSD Ib and are used to study the metabolic and immune consequences of transporter loss.
Point Mutation
Introducing patient-specific mutations (e.g., p.Gly339Asp) into SLC37A4 via CRISPR base editing or homology-directed repair allows precise assessment of how single amino acid changes affect antiport function and disease severity. Such models are critical for genotype-phenotype correlations.
Knock-in
Knock-in of tagged SLC37A4 (e.g., GFP or HA) enables visualization and immunoprecipitation of the transporter in its native context. This approach helps track subcellular localization and interaction partners without overexpression artifacts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of SLC37A4 or other SLC37 family members can enhance antiport activity, providing a gain-of-function system to study transport kinetics and downstream metabolic effects. Overexpression models are also useful for drug screening.
How EDITGENE Supports glucose 6-phosphate:phosphate antiporter activity Research
Researchers studying glucose 6-phosphate:phosphate antiporter activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of SLC37A4 and related genes.
Contact EDITGENE today to design your custom CRISPR model for glucose 6-phosphate:phosphate antiporter activity research.
Frequently Asked Questions About glucose 6-phosphate:phosphate antiporter activity
What is glucose 6-phosphate:phosphate antiporter activity?
It is a molecular function (GO:0061513) that exchanges glucose 6-phosphate and inorganic phosphate across a membrane, typically in the endoplasmic reticulum.
What genes are involved in glucose 6-phosphate:phosphate antiporter activity?
The SLC37 family genes, including SLC37A1, SLC37A2, SLC37A3, and SLC37A4 (G6PT), encode proteins with this activity.
Which diseases are associated with defects in this antiporter?
Mutations in SLC37A4 cause glycogen storage disease type Ib and Ic, characterized by hypoglycemia and neutropenia.
How is glucose 6-phosphate:phosphate antiporter activity measured?
It is commonly measured using radiolabeled substrate transport assays in membrane vesicles or with fluorescent probes in live cells.
What is the reaction catalyzed by this antiporter?
The reaction is: glucose 6-phosphate(out) + phosphate(in) = glucose 6-phosphate(in) + phosphate(out).
Is the antiporter dependent on ATP?
No, it is a secondary active transporter that uses the concentration gradient of phosphate or glucose 6-phosphate, not ATP hydrolysis.
What is the role of SLC37A4 in metabolism?
SLC37A4 transports G6P into the ER for hydrolysis by glucose-6-phosphatase, a key step in hepatic glucose production.
Can CRISPR be used to study this antiporter?
Yes, CRISPR knockout, knock-in, and point mutations in SLC37A4 are powerful tools to model disease and dissect transport mechanisms.
What are the symptoms of glycogen storage disease type Ib?
Symptoms include fasting hypoglycemia, hepatomegaly, neutropenia, and recurrent infections.
How does pH affect the antiporter?
Acidic pH can modulate substrate affinity and transport rates, influencing G6P and Pi exchange.
Conclusion
Glucose 6-phosphate:phosphate antiporter activity (GO:0061513) is a fundamental molecular function that maintains metabolic homeostasis by coupling the exchange of G6P and Pi across cellular membranes. Its dysfunction leads to severe metabolic disorders, notably glycogen storage disease type Ib and Ic, underscoring its clinical importance. Continued research using advanced structural, biochemical, and CRISPR-based approaches will further illuminate its mechanism and therapeutic potential.
References
- 1. Wang Q et al.. 2025. Structures of human glucose-6-phosphate transporter reveal reciprocal antiport mechanism driving glucose-6-phosphate and inorganic phosphate exchange.. Nat Commun 16(1):11441 PMID: 41381426
- 2. Pan CJ et al.. 2011. SLC37A1 and SLC37A2 are phosphate-linked, glucose-6-phosphate antiporters.. PLoS One 6(9):e23157 PMID: 21949678
- 3. Chou JY et al.. 2014. The SLC37 family of sugar-phosphate/phosphate exchangers.. Curr Top Membr 73:357-82 PMID: 24745989
- 4. Kristiansen S et al.. 1994. Effect of glucose-6-phosphate and pH on glucose transport in skeletal muscle plasma membrane giant vesicles.. Acta Physiol Scand 150(2):227-33 PMID: 8191902
- 5. Arion WJ et al.. 1975. On the involvement of a glucose 6-phosphate transport system in the function of microsomal glucose 6-phosphatase.. Mol Cell Biochem 6(2):75-83 PMID: 235736
- 6. Li J et al.. 2011. Glucose-6-phosphate dehydrogenase-dependent hydrogen peroxide production is involved in the regulation of plasma membrane H+-ATPase and Na+/H+ antiporter protein in salt-stressed callus from Carex moorcroftii.. Physiol Plant 141(3):239-50 PMID: 21077901
- 7. Chen SY et al.. 2008. The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic.. FASEB J 22(7):2206-13 PMID: 18337460
- 8. Pan CJ et al.. 2009. Structure-function study of the glucose-6-phosphate transporter, an eukaryotic antiporter deficient in glycogen storage disease type Ib.. Mol Genet Metab 96(1):32-7 PMID: 19008136
